CASE REPORT

Case Report: Novel mutations in TBC1D24 are associated with autosomal dominant tonic-clonic and myoclonic epilepsy and recessive Parkinsonism, psychosis, and intellectual disability [version 1; referees: 2 approved]

Erika Banuelos¹,², Keri Ramsey¹,², Newell Belnap¹,², Malavika Krishnan¹,², Chris Balak¹,², Szabolcs Szelinger¹,², Ashley L. Sniard¹,², Megan Russell¹,², Ryan Richholt¹,², Matt De Both¹,², Ignazio Piras¹,², Marcus Naymik¹,², Ana M. Claasen¹,², Sampathkumar Rangasamy¹,², Matthew J. Huentelman¹,², David W. Craig¹,², Philippe M. Campeau ³, Vinodh Narayanan¹,², Isabelle Schrauwen¹,²

¹Center for Rare Childhood Disorders, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
²Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA
³Department of Pediatrics, CHU Sainte-Justine Research Center and University of Montreal, Montreal, QC, H3T 1C5, Canada

Abstract

Mutations disrupting presynaptic protein TBC1D24 are associated with a variable neurological phenotype, including DOORS syndrome, myoclonic epilepsy, early-infantile epileptic encephalopathy, and non-syndromic hearing loss. In this report, we describe a family segregating autosomal dominant epilepsy, and a 37-year-old Caucasian female with a severe neurological phenotype including epilepsy, Parkinsonism, psychosis, visual and auditory hallucinations, gait ataxia and intellectual disability. Whole exome sequencing revealed two missense mutations in the TBC1D24 gene segregating within this family (c.1078C>T; p.Arg360Cys and c.404C>T; p.Pro135Leu). The female proband who presents with a severe neurological phenotype carries both of these mutations in a compound heterozygous state. The p.Pro135Leu variant, however, is present in the proband’s mother and sibling as well, and is consistent with an autosomal dominant pattern linked to tonic-clonic and myoclonic epilepsy. In conclusion, we describe a single family in which TBC1D24 mutations cause expanded dominant and recessive phenotypes. In addition, we discuss and highlight that some variants in TBC1D24 might cause a dominant susceptibility to epilepsy.
Corresponding authors: Vinodh Narayanan (vnarayanan2@tgen.org), Isabelle Schrauwen (isabelle.schrauwen@gmail.com)

Competing interests: No competing interests were disclosed.

How to cite this article: Banuelos E, Ramsey K, Belnap N et al. Case Report: Novel mutations in TBC1D24 are associated with autosomal dominant tonic-clonic and myoclonic epilepsy and recessive Parkinsonism, psychosis, and intellectual disability [version 1; referees: 2 approved] F1000Research 2017, 6:553 (doi: 10.12688/f1000research.10588.1)

Copyright: © 2017 Banuelos E et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: This work was supported by private donations to TGen’s Center for Rare Childhood Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

First published: 24 Apr 2017, 6:553 (doi: 10.12688/f1000research.10588.1)
Introduction
Mutations in the TBC1D24 gene are the cause of multiple rare disorders whose phenotype consists of varying degrees of intellectual disability, deafness, cortical malformations, and/or epilepsy. To date, the disorders caused by TBC1D24 dysfunction make up a continuum of six distinct phenotypes that include DOORS syndrome (Deafness, Onchohydrotrophy, Osteodystrophy, mental Retardation and Seizures; autosomal recessive; AR), familial infantile myoclonic epilepsy (FIME; AR), progressive myoclonus epilepsy (PME; AR), early-infantile epileptic encephalopathy (EIEE16; AR), autosomal recessive non-syndromic hearing loss (DFNB86; AR), and autosomal dominant non-syndromic hearing loss (DFNA65; AD). TBC1D24 is highly expressed in the brain and can bind ADP ribosylation factor (ARF) 6, a small GTP-binding protein whose function serves to regulate vesicular trafficking. Drosophila with mutations in the sky gene (TBC1D24 orthologue) have a larger readily releasable pool of synaptic vesicles and show a dramatic increase in basal neurotransmitter release. Overall, evidence demonstrates that TBC1D24 is a critical player in synaptic vesicle endocytosis, neurotransmitter release and presynaptic function.

In this report, we describe a single family in which TBC1D24 mutations cause both dominant and recessive phenotypes: dominant tonic-clonic and myoclonic epilepsy, and a recessive severe disorder with epilepsy, Parkinsonian tremor, intellectual disability and psychosis. We discuss and highlight for the first time that dominant inheritance of TBC1D24 mutations might be associated with epilepsy.

Case presentation
A 37-year-old Caucasian female (II:1; Figure 1A) with a complex neurological phenotype characterized by myoclonic epilepsy, cerebellar ataxia, cognitive limitation, fatigue, Parkinsonism, photo-sensitivity and psychosis was referred to TGen’s Center for Rare Childhood Disorders (Supplementary Figure 1).

The patient is the oldest child of a non-consanguineous marriage, born full term by vaginal delivery. At three months of age, she had daily episodes of vomiting, flexing and extending her legs and shaking her arms lasting 30 minutes to 3 hours. At seven months, she developed a Parkinsonian-like tremor in both hands. She experienced focal episodes that included dystonic attacks: spasm of one side of the body, neck, or on one side of her face, in which she was fully conscious.

At 11 months, the patient experienced generalized seizures. At two years, the patient was able to walk, but did so with an unsteady, wide-based gait. She also experienced an upper extremity myoclonus with dystonic features. A neurological examination revealed ptosis, limited upward gaze, and left esotropia. At 2.5 years, a cranial CT scan suggested mild anterior cerebellar atrophy.

The patient’s current symptoms include severe fatigue and an unpredictable sleep cycle. Her speech was delayed (2.5 years onset) and is slow and slightly dysarthric. She was alert and oriented to person and place, but her attention and concentration were reduced. Pure-tone audiometry at 250–8,000 Hz at age 15 showed that she had normal hearing (0–15 db), and tympanometry showed normal stapedial reflexes. She continuously complained of intermittent tinnitus. An ophthalmologic exam at age 13 and 36 showed she had a reduced visual acuity (ETDRS and Snellen acuity testing; OD:40, Snellen 20/160; OS: 36; Snellen 20/200), and optical coherence tomography at age 36 showed a significant retinal and optical nerve thinning (central macular thickness 191 OD, 205 OS, and average nerve rim thickness 71 OD, 67 OS). Intermittent horizontal nystagmus was also observed. Phalanges and nail beds were normal. A physical examination showed that the patient’s muscle tone, strength, and deep tendon reflexes were normal. Although she was able to walk, she had a broad based ataxia (37-years old; Supplementary Video 1). She had dysmetria on nose to finger test, as well as a coarse action tremor. She continues to have involuntary jerking of upper more than lower extremities that last up to an hour. The patient has not had any focal or generalized seizures since the age of 35.

Her cognitive ability was impaired, with a significant decline observed during childhood but no significant change in cognitive ability since adolescence. At age 4.5, a Wechsler Intelligence Scale for Children (WISC-R) test showed an average overall IQ of 93, and at age 8, this was 81. A WISC-III test at 14 years resulted in an IQ score of 65, and at the age of 32 she scored an overall IQ of 67 measured by the Wechsler Adult Intelligence Scale - IV (WAIS-IV). Neuropsychological exams at age 14 and 32 showed severe impairment in the area of visual scanning, working memory, and executive function. She was administered the trail making test and stroop test at the age of 14 and 32 and showed similar scores. For the trail making test, she took 119 seconds to complete trail A as compared to 102 seconds in at age 14. She was unable to complete the trail B task in both occasions. Both of these suggest severe impairment in the area of visual scanning, working memory, and set shifting. The stroop test of executive functioning revealed a severely impaired range on both occasions (age 14 and 32; T < 20). Some variability was seen in the area of working memory. The patient previously performed in the average range on the digit span (age 15), but scored in the mild deficit range on more current testing (age 32). However, on the arithmetic test, which is also a measure of working memory, she previously performed in the severe deficit range, but currently scored in the moderate deficit range. Performance on measures of perceptual reasoning, processing speed and verbal abstraction were impaired as well, as measured by WISC-III and WAIS-IV at age 14 and 32, and remained stable between both ages.

Since 12 years of age, the patient has had episodes of visual and auditory hallucinations. In addition, she suffered from paranoia, agitated behavior, disinhibition and depression. Overall, the patient presents with intellectual disability with increasing symptoms of psychosis.

The patient has undergone two muscle biopsies, and showed little evidence for mitochondrial disease. An increased complex I and IV activity were noted using electron transport studies, although muscle and mitochondrial morphology were normal. Multiple tests for mitochondrial and nuclear DNA mutations were normal. A magnetic resonance imaging (MRI) test in 2014 showed...
Figure 1. Genetic imaging data. (A) Pedigree and inheritance of the variants in TBC1D24, p.Pro135Leu; c.404C>T in exon 2 and p.Arg360Cys; c.1078C>T in exon 4 (NM_001199107.1). (B) Amino acid sequence alignment of both variants between species demonstrating that both amino acids are conserved between species. (C) T1-weighted sagittal MRI scan of brain, illustrating mild cerebellar atrophy affecting the superior vermis. (D) T2-weighted axial MRI scan of the brain showing mild atrophy of the hemispheres. (E) T1-weighted coronal MRI scan of the brain showing mild atrophy of the hemispheres.
mild cerebellar atrophy in the superior cerebellar vermis and the cerebellar hemispheres (Figure 1C–D), and an overnight video EEG showed diffuse mild background slowing consistent with mild cerebral dysfunction, but no epileptiform activity was observed during the test.

The patient’s family history (Figure 1A) is notable in that the mother (I:2) experienced general tonic-clonic seizures before the age of 5, but was not treated with anticonvulsants. The mother also noted that her father had similar episodes. The mother also reported the presence of hearing loss starting at the age of 40, and needed hearing aids in both ears by the age of 60. Moreover, the patient’s older brother (II:2) experienced general myoclonic spells similar to that of the patient and was treated with anticonvulsants through the age of 18.

Methods

Sequencing

DNA was extracted from the blood of both parents and proband. Exomic libraries were prepared with the SureSelect All Human XT v5 exome kits (Agilent Technologies, Santa Clara, CA, USA), following the manufacturer’s protocol. Sequencing was performed by 101bp paired-end sequencing on a HiSeq2000 instrument (Illumina Inc, San Diego, CA, USA). Filtered reads were aligned to the Human genome (Hg19/GRCh37) using the Burrows-Wheeler transform (BWA-MEM; v0.7.8). Reads where sorted and polymerase chain reaction (PCR) duplicates were removed using Picard (v1.111) and base quality recalibration, indel realignment were performed using the Genome Analysis Toolkit (GATK; v3.1-1). Variants were called jointly with HaplotypeCaller and recalibrated with GATK, annotated with dbNSFP (v2.9) and snpEff (3.5h) for protein-coding events. Prediction scores were loaded from dbNSFP (v2.9) and used for filtering.

Sanger sequencing was performed on the proband and brother by GeneDx (Gaithersburg, MD, USA), and on the parents by the authors. In short, the target areas of the gene were PCR amplified and capillary sequencing was performed. A bi-directional sequence was assembled, aligned to reference gene sequences based on human genome build GRCh37/UCSC hg19 and analyzed for known familial sequence variant(s) (Applied Biosystems Inc., Foster City, CA, USA).

Results

Exome sequencing in the proband and parents led to the identification of compound heterozygote mutations in TBC1D24 in the patient (II:1), p.Pro135Leu; c.404C>T in exon 2 and p.Arg360Cys; c.1078C>T in exon 4 (NM_001199107.1) (Figure 1). These mutations were confirmed by Sanger sequencing in the entire pedigree (Figure 1). Neither variant was observed in the ExAC Browser database of 60,706 unrelated individuals[26], and both were predicted to be damaging by Polyphen 2, MutationTaster, have a high combined annotation dependent depletion (CADD) score (26.5 and 17.7 for P135L and R360C respectively) and are conserved between species (Figure 1B). Both the mother and younger brother, affected by seizures at younger ages, are heterozygous for the p.Pro135Leu variant. The father is carrier of the p.Arg360Cys variant and asymptomatic (Figure 1A).

Discussion

We identified two previously unreported pathogenic variants in the TBC1D24 gene that segregate in a family with a severe complex neurological disorder and tonic-clonic and myoclonic epilepsy (p.Pro135Leu and p.Arg360Cys; Figure 1A). The p.Pro135Leu missense mutation follows an autosomal dominant pattern associated with mild seizures in the proband, mother and younger brother. The proband shows a severe but atypical recessive TBC1D24 neurological phenotype and is compound heterozygote for p.Pro135Leu and p.Arg360Cys. The p.Arg360Cys carrier shows no clinical symptoms.

Mutations in TBC1D24 so far have shown to cause an autosomal recessive variable phenotype, ranging from non-syndromic hearing loss, epileptic disorders, to DOORS syndrome[1]. An autosomal dominant inheritance pattern has only been described in cases with non-syndromic slowly progressive adult onset hearing impairment[12]. However, there are other reported cases of TBC1D24 mutation carriers who had seizures, such as the mother of a child with DOORS syndrome, who carries a frameshift mutation (c.1008delT, p.His336GlnfsTer12*) and who had absence seizures as a child[1]. In another family with recessive deafness caused by TBC1D24 mutation, a heterozygous carrier of a missense mutation (c.208G>T, p.Asp70Tyr) had epilepsy since the age of 3 continuing in adulthood (individual IV-8 of pedigree PDKF799 in [14]). In another family, the mother and half-sister of an individual carrying the NM_001199107.1:c.32A>G, p.Asp11Gly mutation had epilepsy beginning in adulthood (they were not tested for the mutation)[15]. Finally, the father of a patient with the following TBC1D24 mutations, c.1460dupA, p.His487Glnfs*71 and c.313T>C, p.Cys105Arg, also had a history of seizures[1]. While it is difficult to attribute with certainty the epilepsy in these carriers or possible carriers to the TBC1D24 mutations, the incidence of epilepsy in carriers is higher than what would be expected by a chance co-occurrence, given that there are less than 40 families described thus far and the prevalence of epilepsy in the general population is 7 per 1000 individuals[48]. Moreover, as suggested with the family we describe here, some variants might be more susceptible to cause dominant epilepsy. With regards to Parkinsonism, it was previously described in one individual with DOORS syndrome who was later found to have two TBC1D24 mutations (c.619C>T, p.Gln207* and c.1126G>C, p.Gly376Arg, PMID: 27281533)[3].

The behavior of the p.Pro135Leu variant is distinct from previous reported variants, and is of interest as it acts almost in a semi- or partial dominant manner. This variant occurs at a highly conserved position in the Rab-GAP N-terminal Tre2–Bub2–Cdc16 (TBC) domain of the protein. It was recently discovered that this domain directly binds phosphoinositides through a cationic pocket and that phosphoinositide binding is critical for presynaptic function[4]. A fly model with 3 clinically pathogenic mutations (3Glu mutant) in the phosphoinositide-binding pocket causes severe neurological defects, including impaired synaptic-vesicle trafficking and seizures[5].

The p.Arg360Cys variant is located between the TBC and TBC–LysM (TLDc) domain. p.Arg360Leu, a change at the same
site as p.Arg360Cys, has been described in a recessive state in a patient with progressive myoclonus epilepsy\textsuperscript{18}. Functional studies in primary mouse cortical cells transfected with p.Arg360Leu mutant showed a significant reduced induction of outgrowth in neurite length compared to wild-type\textsuperscript{1}. Both p.Arg360Leu and p.Arg360Cys only seem to exhibit a clinical phenotype in a recessive or compound heterozygote state in this and previous studies\textsuperscript{18}.

In conclusion, this family’s clinical presentation highlights the broad spectrum of both AD and AR TBC1D24 disorders, including Parkinsonism, psychiatric symptoms, and autosomal dominant tonic-clonic and myoclonic epilepsy.

**Data availability**

Exome data of individuals have been added to the Database of Genotypes and Phenotypes (dbGaP; http://www.ncbi.nlm.nih.gov/gap) under project phs000816. Both variants have been reported to ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) under variation IDs SCV000494664 (p.Arg360Cys), SCV000494665 and SCV000494666 (p.Pro135Leu; NM_001199107.1). The raw sequence data of the father (C4RCD_0194), mother (C4RCD_0193), and propositus (C4RCD_0192) were submitted to the Sequence Read Archive (SRA; http://www.ncbi.nlm.nih.gov/sra) with the respective Biosample ID numbers SAMN05687268, SAMN05687209 and SAMN05687491.

**Consent**

Written informed consent for publication of their clinical details, (identifiable) clinical images and videos was obtained from the legally authorized representative (as the patient has a diminished decision-making capacity, due to her intellectual disability and her disorder described here) and the patient’s family. The study was explained to the extent compatible with the subject’s understanding, and was enrolled into the Center for Rare Childhood Disorders program at the Translational Genomics Research Institute (TGen). The study protocol and consent procedure was approved by the Western Institutional Review Board (study number, 20120789).

**Author contributions**

EB, IS and MK prepared the first draft of the manuscript. KR, NB, PMC and VN contributed towards the clinical summary, discussion and assessed the patient. SS, ALS, CB, AMC performed the sequencing, and MR, RR, MDB, IP, and MN performed bioinformatics analysis. KR, NB, SS, ALS, MR, RR, MDB, CB, IP, MN, AMC, SR, DWG, MJH, IS and VN contributed to the experimental design. All authors provided expertise in genomics and were involved in the revision of the draft manuscript and have agreed to the final content.

**Competing interests**

No competing interests were disclosed.

**Grant information**

This work was supported by private donations to TGen’s Center for Rare Childhood Disorders.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Acknowledgements**

The authors thank the family for participating in this study and all the previous members of the C4RCD research group not included in the author list, including previous member Jason J. Corneveaux.
5. Wechsler D: *Wechsler Intelligence Scale for Children-Revised*. In Psychological Corporation, 1974. Reference Source

6. Wechsler D: *WISC-III: Wechsler Intelligence Scale for Children*: Manual. 3rd ed. Psychological Corporation, 1991; 294. Reference Source

7. Wechsler D: *Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV)*. In: 4th ed. Pearson Education, 2008. Reference Source

8. Stroop JR: *Studies of interference in serial verbal reactions*. J Exp Psychol. Psychological Review Company; 1935; 18(6): 643–62. Publisher Full Text

9. Tombaugh TN: *Trail Making Test A and B: Normative data stratified by age and education*. Arch Clin Neuropsychol. 2004; 19(2): 203–14. PubMed Abstract | Publisher Full Text

10. Lek M, Karczewski KJ, Minikel EV, et al.: *Analysis of protein-coding genetic variation in 60,706 humans*. Nature. 2016; 536(7616): 285–91. PubMed Abstract | Publisher Full Text | Free Full Text

11. Kircher M, Witten DM, Jain P, et al.: *A general framework for estimating the relative pathogenicity of human genetic variants*. Nat Genet. Nature Publishing Group, A division of Macmillan Publishers Limited. 2014; 46(3): 310–5. PubMed Abstract | Publisher Full Text | Free Full Text

12. Azaiez H, Booth KT, Bu F, et al.: *TBC1D24 mutation causes autosomal-dominant nonsyndromic hearing loss*. Hum Mutat. 2014; 35(7): 819–23. PubMed Abstract | Publisher Full Text | Free Full Text

13. Campseau PM, Kasperaviciute D, Lu JT, et al.: *The genetic basis of DOORS syndrome: an exome-sequencing study*. Lancet Neurol. 2014; 13(1): 44–58. PubMed Abstract | Publisher Full Text | Free Full Text

14. Rehman AU, Santos-Cortez RL, Morell RJ, et al.: *Mutations in TBC1D24, a gene associated with epilepsy, also cause nonsyndromic deafness DFNB86*. Am J Hum Genet. 2014; 94(1): 144–52. PubMed Abstract | Publisher Full Text | Free Full Text

15. Stražišar BG, Neubauer D, Poro Panjan D, et al.: *Early-onset epileptic encephalopathy with hearing loss in two siblings with TBC1D24 recessive mutations*. Eur J Paediatr Neurol. 2015; 19(2): 251–6. PubMed Abstract | Publisher Full Text

16. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al.: *How common are the “common” neurologic disorders?* Neurology. 2007; 68(5): 326–37. PubMed Abstract | Publisher Full Text

17. Bilo L, Peluso S, Antenora A, et al.: *Parkinsonism may be part of the symptom complex of DOOR syndrome*. Parkinsonism Relat Disord. 2014; 20(4): 463–5. PubMed Abstract | Publisher Full Text

18. Muona M, Berkovic SF, Dibbens LM, et al.: *A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy*. Nat Genet. Europe PMC Funders, 2015; 47(1): 39–46. PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Referee Status: ✔ ✔

Version 1

Referee Report 13 June 2017
doi:10.5256/f1000research.11410.r23438

Brian Appavu
Columbia University Medical Center, New York, NY, USA

I read this case report with great interest. TBC1D24-related diseases represent a unique subset of conditions for which the rapid emergence of both clinical and basic science data has helped elucidate insight into the pathophysiology of this condition. This case report adds to the existing literature of TBC1D24-related diseases, and suggests a novel inheritance pattern in which an autosomal-dominant pattern of inheritance leads to a phenotype that includes epilepsy. This paper can benefit from minor revisions.

1. With regard to the case presentation, were any seizures or specific episodes of myoclonus captured on video EEG monitoring? If so, what did they show? If myoclonus was captured, did it appear either cortical or subcortical?

2. The terms, variant and mutation are used at various points throughout the manuscript. To make the terminology clear, I would refer to those mutations that are pathogenic as pathologic variants, rather than mutations.

3. Discussion, paragraph 2 line 1: For grammatical purposes, change the following line to "Mutations in TBC1D24 so far have been shown to cause an autosomal recessive variable phenotype, ranging from non-syndromic hearing loss to epileptic disorders and DOORS syndrome"

4. Discussion, paragraph 2 line 7: Did epilepsy begin at 3 months or 3 years of age? Be specific.

5. Conclusion: Given that this is the first paper to suggest an an autosomal-dominant mode of inheritance for TBC1D24-related epilepsy, commentary regarding the need for further functional studies of this and other related variants would help strengthen this manuscript.

Is the background of the case’s history and progression described in sufficient detail?
Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Is the background of the case’s history and progression described in sufficient detail?
Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Yes

Is the case presented with sufficient detail to be useful for other practitioners?
Yes

_Competing Interests_: I have worked two of the authors within the manuscript at a clinical level.

_Referee Expertise_: My area of interest is in epilepsy and EEG

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

_referee report 03 May 2017_
doi:10.5256/f1000research.11410.r22162

Deepa S. Rajan
Division of Child Neurology, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

Interesting Case.
1. In the attached video, the phenotype would most likely fit into ataxia/ wide based gait/ cerebellar origin in my opinion and think that the term parkinsonism might be misleading. Other than the mentioned tremor were there any other features to suspect extrapyramidal disease?

2. Were there any other variant of currently unknown significance on the exome?

_Is the background of the case's history and progression described in sufficient detail?_
Yes

_Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?_
Partly

_Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?_
Yes

_Is the case presented with sufficient detail to be useful for other practitioners?_
Yes

_Competing Interests_: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.